Literature DB >> 31682969

Predicting Survival for Patients With Metastatic Disease.

Kathryn R K Benson1, Sonya Aggarwal1, Justin N Carter1, Rie von Eyben1, Pooja Pradhan1, Nicolas D Prionas1, Justin L Bui1, Scott G Soltys1, Steven Hancock1, Michael F Gensheimer1, Albert C Koong2, Daniel T Chang3.   

Abstract

PURPOSE: This prospective study aimed to determine the accuracy of radiation oncologists in predicting the survival of patients with metastatic disease receiving radiation therapy and to understand factors associated with their accuracy. METHODS AND MATERIALS: This single-institution study surveyed 22 attending radiation oncologists to estimate patient survival. Survival predictions were defined as accurate if the observed survival (OS) was within the correct survival prediction category (0-6 months, >6-12 months, >12-24 months, and >24 months). The physicians made survival estimates for each course of radiation, yielding 877 analyzable predictions for 689 unique patients. Data analysis included Stuart's Tau C, logistic regression models, ordinal logistic regression models, and stepwise selection to examine variable interactions.
RESULTS: Of the 877 radiation oncologists' predictions, 39.7% were accurate, 26.5% were underestimations, and 33.9% were overestimations. Stuart's Tau C showed low correlation between OS and survival estimates (0.3499), consistent with the inaccuracy reported in the literature. However, results showed less systematic overprediction than reported in the literature. Karnofsky performance status was the most significant predictor of accuracy, with greater accuracy for patients with shorter OS. Estimates were also more accurate for patients with lower Karnofsky performance status. Accuracy by patient age varied by primary site and race. Physician years of experience did not correlate with accuracy.
CONCLUSIONS: The sampled radiation oncologists have a 40% accuracy in predicting patient survival. Future investigation should explore how survival estimates influence treatment decisions and how to improve survival prediction accuracy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31682969     DOI: 10.1016/j.ijrobp.2019.10.032

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Automated model versus treating physician for predicting survival time of patients with metastatic cancer.

Authors:  Michael F Gensheimer; Sonya Aggarwal; Kathryn R K Benson; Justin N Carter; A Solomon Henry; Douglas J Wood; Scott G Soltys; Steven Hancock; Erqi Pollom; Nigam H Shah; Daniel T Chang
Journal:  J Am Med Inform Assoc       Date:  2021-06-12       Impact factor: 4.497

2.  External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life.

Authors:  Adrianna E Mojica-Márquez; Joshua L Rodríguez-López; Ankur K Patel; Diane C Ling; Malolan S Rajagopalan; Sushil Beriwal
Journal:  Cancer Med       Date:  2020-06-26       Impact factor: 4.452

3.  Comparable prevalence of distant metastasis and survival of different primary site for LN + pancreatic tumor.

Authors:  Xin Lou; Jun Li; Ya-Qing Wei; Zhi-Jia Jiang; Ming Chen; Jin-Jin Sun
Journal:  J Transl Med       Date:  2020-07-01       Impact factor: 5.531

4.  Association of radiation dose intensity with overall survival in patients with distant metastases.

Authors:  Johnny Kao; Mark K Farrugia; Samantha Frontario; Amanda Zucker; Emily Copel; John Loscalzo; Ashish Sangal; Boramir Darakchiev; Anurag Singh; Symeon Missios
Journal:  Cancer Med       Date:  2021-09-30       Impact factor: 4.452

5.  Prognostication in palliative radiotherapy-ProPaRT: Accuracy of prognostic scores.

Authors:  Marco Maltoni; Emanuela Scarpi; Monia Dall'Agata; Simona Micheletti; Maria Caterina Pallotti; Martina Pieri; Marianna Ricci; Antonino Romeo; Maria Valentina Tenti; Luca Tontini; Romina Rossi
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.